Advances in basic research, clinical diagnosis and treatment of thyroid cancer in 2022

Ning QU; Yuting WANG; Ben MA; Yu WANG

doi:10.19401/j.cnki.1007-3639.2023.05.001

您当前的位置：

首页 >

文章列表页 >

Advances in basic research, clinical diagnosis and treatment of thyroid cancer in 2022

Specialists' Commentary | 更新时间：2025-12-31

- Advances in basic research, clinical diagnosis and treatment of thyroid cancer in 2022
- China Oncology Vol. 33, Issue 5, Pages: 423-430(2023)
- 作者机构：
  
  复旦大学附属肿瘤医院头颈外科，复旦大学上海医学院肿瘤学系，上海 200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2023.05.001
  CLC： R736.1
- Received：20 March 2023，
  
  Revised：2023-05-08，
  
  Published：30 May 2023
- 稿件说明：
移动端阅览
Ning QU, Yuting WANG, Ben MA, et al. Advances in basic research, clinical diagnosis and treatment of thyroid cancer in 2022[J]. China Oncology, 2023, 33(5): 423-430.
DOI：

Ning QU, Yuting WANG, Ben MA, et al. Advances in basic research, clinical diagnosis and treatment of thyroid cancer in 2022[J]. China Oncology, 2023, 33(5): 423-430. DOI： 10.19401/j.cnki.1007-3639.2023.05.001.

摘要

甲状腺癌是近年来发病率显著升高的内分泌系统恶性肿瘤，治疗以外科治疗为主，术后根据情况辅以内分泌治疗、放射性核素治疗，某些情况下需辅以放疗、靶向治疗。然而甲状腺癌的死亡率亦有升高趋势，晚期或低分化/去分化患者的预后差且生存时间短。基础和临床研究的推进，使得甲状腺癌的个体化治疗取得了新进展。现对2022年度甲状腺癌领域的研究进展进行综述。

Abstract

Thyroid cancer is a common malignancy of the endocrine system with a significantly increased incidence in recent years. Surgical treatment is the primary treatment

followed by endocrine therapy and radionuclide therapy according to the clinical evaluations

and in some cases

radiotherapy and targeted therapy are needed. However

the mortality of thyroid cancer also tends to increase

especially in advanced or low/dedifferentiated patients with poor prognosis and short survival time. With the advancement of basic and clinical research

new progress has been made in individualized treatment of thyroid cancer. This article reviewed the research progress of thyroid cancer in 2022.

关键词

Keywords

references

ZHENG R , ZHANG S , ZENG H , et al . Cancer incidence and mortality in China, 2016 [J ] . J Natl Cancer Center , 2022 , 2 ( 1 ): 1 - 9 DOI: 10.1016/j.jncc.2022.02.002 http://doi.org/10.1016/j.jncc.2022.02.002 https://linkinghub.elsevier.com/retrieve/pii/S2667005422000047 https://linkinghub.elsevier.com/retrieve/pii/S2667005422000047

ZHOU M G , WANG H D , ZENG X Y , et al . Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [J ] . Lancet , 2019 , 394 ( 10204 ): 1145 - 1158 . DOI: S0140-6736(19)30427-1 http://doi.org/S0140-6736(19)30427-1

张新洲 , 刘劲松 , 许娴 , 等 . 2005—2016年中国甲状腺癌发病和死亡趋势分析 [J ] . 中华肿瘤防治杂志 , 2022 , 29 ( 24 ): 1725 - 1733 .

ZHANG X Z , LIU J S , XU X , et al . Trends of thyroid cancer incidence and mortality in China from 2005 to 2016 [J ] . Chin J Cancer Prev Treat , 2022 , 29 ( 24 ): 1725 - 1733 .

CHEN W Q , ZHENG R S , ZUO T T , et al . National cancer incidence and mortality in China, 2012 [J ] . Chin J Cancer Res , 2016 , 28 ( 1 ): 1 - 11 .

HONGMEI , ZENG , PHD , et al . Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries [J ] . Lancet Glob Health , 2018 , 6 ( 5 ): e555-e567.

VACCARELLA S , LORTET-TIEULENT J , COLOMBET M , et al . Global patterns and trends in incidence and mortality of thyroid cancer in children and adolescents: a population-based study [J ] . Lancet Diabetes Endocrinol , 2021 , 9 ( 3 ): 144 - 152 . DOI: 10.1016/S2213-8587(20)30401-0 http://doi.org/10.1016/S2213-8587(20)30401-0 https://linkinghub.elsevier.com/retrieve/pii/S2213858720304010 https://linkinghub.elsevier.com/retrieve/pii/S2213858720304010

黄志刚 , 陈晓红 . 分化型甲状腺癌个体化分层治疗的策略和意义 [J ] . 中华耳鼻咽喉头颈外科杂志 , 2017 , 52 ( 6 ): 405 - 409

HUANG Z G , CHEN X H . The strategy and significance of individualized stratified therapy for differentiated thyroid carcinoma [J ] . Chin J Otorhinolaryngol Head Neck Surg , 2017 , 52 ( 6 ): 405 - 409 .

ROMEI C , CIAMPI R , ELISEI R . A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma [J ] . Nat Rev Endocrinol , 2016 , 12 ( 4 ): 192 - 202 . DOI: 10.1038/nrendo.2016.11 http://doi.org/10.1038/nrendo.2016.11

贺青卿 , 于芳 , 范子义 , 等 . 单中心2 038例甲状腺癌20年随访及危险因素分析 [J ] . 中华内分泌外科杂志 , 2022 , 16 ( 1 ): 18 - 22 .

HE Q Q , YU F , FAN Z Y , et al . Risk factor analysis of 20-year follow-up of 2 038 cases of thyroid cancer: a single center study [J ] . Chin J Endocr Surg , 2022 , 16 ( 1 ): 18 - 22 .

LI X C , ZHANG S , ZHANG Q , et al . Diagnosis of thyroid cancer using deep convolutional neural network models applied to sonographic images: a retrospective, multicohort, diagnostic study [J ] . Lancet Oncol , 2019 , 20 ( 2 ): 193 - 201 . DOI: S1470-2045(18)30762-9 http://doi.org/S1470-2045(18)30762-9

FRANCO A T , RICARTE-FILHO J C , ISAZA A , et al . Fusion oncogenes are associated with increased metastatic capacity and persistent disease in pediatric thyroid cancers [J ] . J Clin Oncol , 2022 , 40 ( 10 ): 1081 - 1090 . DOI: 10.1200/JCO.21.01861 http://doi.org/10.1200/JCO.21.01861

DOOLITTLE W K L , ZHAO L , CHENG S Y . Blocking CDK7-mediated NOTCH1-cMYC signaling attenuates cancer stem cell activity in anaplastic thyroid cancer [J ] . Thyroid , 2022 , 32 ( 8 ): 937 - 948 . DOI: 10.1089/thy.2022.0087 http://doi.org/10.1089/thy.2022.0087

ZHANG P T , GUAN H X , YUAN S K , et al . Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF -mutant papillary thyroid cancer to MAPK inhibitors [J ] . Nat Commun , 2022 , 13 ( 1 ): 1588 . DOI: 10.1038/s41467-022-29000-5 http://doi.org/10.1038/s41467-022-29000-5

孙海燕 , 弓磊 , 于振涛 , 等 . 髓源性抑制细胞联合免疫检查点抑制剂抗肿瘤治疗的研究进展 [J ] . 肿瘤防治研究 , 2020 , 47 ( 9 ) 716 - 721

SUN H Y , GONG L , YU Z T , et al . Advances in anti-tumor therapy of myeloid-derived suppressor cells combined with immunological checkpoint inhibitors [J ] . Cancer Res Prev Treat , 2020 , 47 ( 9 ) 716 - 721

RABOLD K , ZOODSMA M , GRONDMAN I , et al . Reprogramming of myeloid cells and their progenitors in patients with non-medullary thyroid carcinoma [J ] . Nat Commun , 2022 , 13 ( 1 ): 6149 . DOI: 10.1038/s41467-022-33907-4 http://doi.org/10.1038/s41467-022-33907-4

YIP L , SOSA J A . Molecular-directed treatment of differentiated thyroid cancer: advances in diagnosis and treatment [J ] . JAMA Surg , 2016 , 151 ( 7 ): 663 - 670 . DOI: 10.1001/jamasurg.2016.0825 http://doi.org/10.1001/jamasurg.2016.0825

PENG S , LIU Y H , LV W M , et al . Deep learning-based artificial intelligence model to assist thyroid nodule diagnosis and management: a multicentre diagnostic study [J ] . Lancet Digit Health , 2021 , 3 ( 4 ): e250-e259.

MONTERO-CONDE C , LEANDRO-GARCÍA L J , et al .MARTÍNEZ-MONTES Á M, Comprehensive molecular analysis of immortalization hallmarks in thyroid cancer reveals new prognostic markers [J ] . Clin Transl Med , 2022 , 12 ( 8 ): e1001.

SUN Y T , SELVARAJAN S , ZANG Z L , et al . Artificial intelligence defines protein-based classification of thyroid nodules [J ] . Cell Discov , 2022 , 8 ( 1 ): 85 . DOI: 10.1038/s41421-022-00442-x http://doi.org/10.1038/s41421-022-00442-x

SHI X , SUN Y , SHEN C , et al . Integrated proteogenomic characterization of medullary thyroid carcinoma [J ] . Cell Discov , 2022 , 8 ( 1 ): 120 . DOI: 10.1038/s41421-022-00479-y http://doi.org/10.1038/s41421-022-00479-y

National Cancer Center , Thyroid Cancer Expert Committee of National Cancer Quality Control Center . Quality control index for standardized diagnosis and treatment of thyroid cancer in China (2022 edition) [J ] . Chin J Oncol , 2022 , 44 ( 9 ): 902 - 907 .

FILETTI S , DURANTE C , HARTL D , et al . Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [J ] . Ann Oncol , 2019 , 30 ( 12 ): 1856 - 1883 . DOI: S0923-7534(20)32555-2 http://doi.org/S0923-7534(20)32555-2

ZHANG Z Y , SUN B T , OUYANG H , et al . Endoscopic lateral neck dissection: a new frontier in endoscopic thyroid surgery [J ] . Front Endocrinol (Lausanne) , 2021 , 12 : 796984 . DOI: 10.3389/fendo.2021.796984 http://doi.org/10.3389/fendo.2021.796984 https://www.frontiersin.org/articles/10.3389/fendo.2021.796984/full https://www.frontiersin.org/articles/10.3389/fendo.2021.796984/full

中国抗癌协会 . 中国肿瘤整合诊治指南(CACA)甲状腺癌2022版 [M ] . 天津科学技术出版社 , 2022 .

China Anti-Cancer Association . China Cancer Integrated Diagnosis and Treatment Guidelines (CACA) for thyroid cancer 2022 edition [M ] . Tianjin Science and Technology Press , 2022 .

中华人民共和国国家卫生健康委员会医政医管局 . 甲状腺癌诊疗指南(2022年版) [J ] . 中国实用外科杂志 , 2022 , 42 ( 12 ): 1343 - 1357 , 1363.

National Health Commission of the People’s Republic of China Medical Administration and Hospital Administration . Guidelines for the diagnosis and treatment of thyroid carcinoma [J ] . Chin J Pract Surg , 2022 , 42 ( 12 ): 1343 - 1357 , 1363.

纪玲霞 , 周爱琴 , 周雪梅 . 调强放疗治疗甲状腺癌术后残留和复发的临床效果研究 [J ] . 实用癌症杂志 , 2022 , 37 ( 5 ): 858 - 860

JI L X , ZHOU A Q , ZHOU X M . Clinical study on the effect of intensive modulation radiotherapy in the treatment of residue and recurrence after thyroid cancer [J ] . Pract J Cancer , 2022 , 37 ( 5 ): 858 - 860

KWON J , KIM B H , JUNG H W , et al . The prognostic impacts of postoperative radiotherapy in the patients with resected anaplastic thyroid carcinoma: a systematic review and meta-analysis [J ] . Eur J Cancer , 2016 , 59 : 34 - 45 . DOI: S0959-8049(16)00130-1 http://doi.org/S0959-8049(16)00130-1

ORLANDI F , CARACI P , BERRUTI A , et al . Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer [J ] . Ann Oncol , 1994 , 5 ( 8 ): 763 - 765 .

SCHLUMBERGER M , LEBOULLEUX S . Current practice in patients with differentiated thyroid cancer [J ] . Nat Rev Endocrinol , 2021 , 17 ( 3 ): 176 - 188 . DOI: 10.1038/s41574-020-00448-z http://doi.org/10.1038/s41574-020-00448-z

HO A L , DEDECJUS M , WIRTH L J , et al . Selumetinib plus adjuvant radioactive iodine in patients with high-risk differentiated thyroid cancer: a phase Ⅲ, randomized, placebo-controlled trial (ASTRA) [J ] . J Clin Oncol , 2022 , 40 ( 17 ): 1870 - 1878 . DOI: 10.1200/JCO.21.00714 http://doi.org/10.1200/JCO.21.00714 https://ascopubs.org/doi/10.1200/JCO.21.00714 https://ascopubs.org/doi/10.1200/JCO.21.00714

CAO J J , ZHU X L , SUN Y R , et al . The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer [J ] . Eur J Nucl Med Mol Imaging , 2022 , 49 ( 10 ): 3470 - 3481 . DOI: 10.1007/s00259-022-05820-x http://doi.org/10.1007/s00259-022-05820-x

NABHAN F , DEDHIA P H , RINGEL M D . Thyroid cancer, recent advances in diagnosis and therapy [J ] . Int J Cancer , 2021 , 149 ( 5 ): 984 - 992 . DOI: 10.1002/ijc.33690 http://doi.org/10.1002/ijc.33690

National Comprehensive Cancer Network . NCCN clinical practice guidelines in thyroid cancer (2022 version Ⅰ) [DB/OL ] . [ 2023-04-28 ] . http://www.nccn.org. http://www.nccn.org http://www.nccn.org

SUBBIAH V , KREITMAN R J , WAINBERG Z A , et al . Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase Ⅱ ROAR basket study [J ] . Ann Oncol , 2022 , 33 ( 4 ): 406 - 415 . DOI: 10.1016/j.annonc.2021.12.014 http://doi.org/10.1016/j.annonc.2021.12.014 https://linkinghub.elsevier.com/retrieve/pii/S0923753422000059 https://linkinghub.elsevier.com/retrieve/pii/S0923753422000059

HUANG N S , WEI W J , XIANG J , et al . The efficacy and safety of anlotinib in neoadjuvant treatment of locally advanced thyroid cancer: a single-arm phase Ⅱ clinical trial [J ] . Thyroid , 2021 , 31 ( 12 ): 1808 - 1813 . DOI: 10.1089/thy.2021.0307 http://doi.org/10.1089/thy.2021.0307 https://www.liebertpub.com/doi/10.1089/thy.2021.0307 https://www.liebertpub.com/doi/10.1089/thy.2021.0307

SARONNI D , GAUDENZI G , DICITORE A , et al . Preclinical evaluation of novel tyrosine-kinase inhibitors in medullary thyroid cancer [J ] . Cancers (Basel) , 2022 , 14 ( 18 ): 4442 . DOI: 10.3390/cancers14184442 http://doi.org/10.3390/cancers14184442 https://www.mdpi.com/2072-6694/14/18/4442 https://www.mdpi.com/2072-6694/14/18/4442

中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤学会(CSCO)分化型甲状腺癌诊疗指南2021 [J ] . 肿瘤预防与治疗 , 2021 , 34 ( 12 ): 1164 - 1201 .

Working Committee of the Guidelines of the Chinese Society of Clinical Oncology . Guidelines of Chinese Society of Clinical Oncology (CSCO) differentiated thyroid cancer [J ] . J Cancer Control Treat , 2021 , 34 ( 12 ): 1164 - 1201 .

SUBBIAH V , HU M I , WIRTH L J , et al . Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study [J ] . Lancet Diabetes Endocrinol , 2021 , 9 ( 8 ): 491 - 501 . DOI: 10.1016/S2213-8587(21)00120-0 http://doi.org/10.1016/S2213-8587(21)00120-0 https://linkinghub.elsevier.com/retrieve/pii/S2213858721001200 https://linkinghub.elsevier.com/retrieve/pii/S2213858721001200

RAMAN R , VILLEFRANC J A , ULLMANN T M , et al . Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET-rearranged thyroid cancer [J ] . J Exp Med , 2022 , 219 ( 6 ): e20210390.

LEE Y A , LEE H , IM S W , et al . NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake [J ] . J Clin Invest , 2021 , 131 ( 18 ): e144847.

WAGUESPACK S G , DRILON A , LIN J J , et al . Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma [J ] . Eur J Endocrinol , 2022 , 186 ( 6 ): 631 - 643 . DOI: 10.1530/EJE-21-1259 http://doi.org/10.1530/EJE-21-1259 https://academic.oup.com/ejendo/article/186/6/631/6853698 https://academic.oup.com/ejendo/article/186/6/631/6853698

Views

7456

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Advances in basic research, clinical diagnosis and treatment of prostate cancer in 2022

Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2021

Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2019

Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2018

Recent advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2017

Related Author

Jian PAN

Yao ZHU

Bo DAI

Dingwei YE

Xinzhe ZHU

Hao LI

Huaxiang XU

Guopei LUO

Related Institution

Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University; Pancreatic Cancer Institute, Fudan University; Shanghai Pancreatic Cancer Institute

复旦大学附属肿瘤医院胰腺外科，复旦大学胰腺肿瘤研究所，上海市胰腺肿瘤研究所，复旦大学上海医学院肿瘤学系

复旦大学附属肿瘤医院胰腺外科、胰腺癌研究所，复旦大学上海医学院肿瘤学系

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai Pancreatic Cancer Institute, Shanghai Key Laboratory of Precision Medicine for Pancreatic Cancer, Pancreatic Cancer Institute, Fudan University

AI问答

⁰